Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials

To evaluate outcomes and disease characteristics in eyes with neovascular age-related macular degeneration that received intravitreal aflibercept injection (IAI) and ranibizumab every 12  weeks or longer (≥q12 weeks) or less than every 12 weeks (

Source: American Journal of Ophthalmology - January 17, 2019 Category: Opthalmology Authors: Rahul N. Khurana, Ehsan Rahimy, W. Anthony Joseph, Namrata Saroj, Andrea Gibson, Robert Vitti, Alyson J. Berliner, Karen Chu, YenChieh Cheng, David S. Boyer Tags: Original article Source Type: research